Ionis Pharmaceuticals, Inc.
Modified compounds and uses thereof

Last updated:

Abstract:

The present disclosure provides oligomeric compound comprising a modified oligonucleotide having a central region comprising one or more modifications. In certain embodiments, the present disclosure provides oligomeric compounds having an improved therapeutic index or an increased maximum tolerated dose.

Status:
Grant
Type:

Utility

Filling date:

12 Feb 2019

Issue date:

17 May 2022